Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction

The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review

(2020) Trinidad Montero‐Vilchez et al.   Dermatologic Therapy

Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review

(2020) T. Montero-Vilchez et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

(2019) Jorge Romaní et al.   DERMATOLOGY

Ustekinumab treatment for hidradenitis suppurativa

(2019) Kana Takeda et al.   JOURNAL OF DERMATOLOGY

Part 2. Current and emerging treatments for hidradenitis suppurativa

(2019) Samantha R. Goldburg et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ustekinumab, another biologic with potential to help patients with hidradenitis suppurativa?

(2016) D.B. Eisen   BRITISH JOURNAL OF DERMATOLOGY

Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum

(2016) J.L. Blok et al.   BRITISH JOURNAL OF DERMATOLOGY

Experience with ustekinumab for the treatment of moderate to severe Hidradenitis suppurativa

(2011) W.P. Gulliver et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY